Founded in 2005, Korea Institute for Pharmaceutical Policy Affairs, KIPPA, is a non-profit, public foundation, approved by the Korean Ministry of Health and Welfare. The institute is contributed by three relevant parties, the Korean Pharmaceutical Association (KPA), the Korea Pharmaceutical and Bio-Pharma Manufacturers Association (KBPMA), and the Korea Pharmaceutical Distribution Association (KPDA).

KIPPA is a leading research center, which aims to promote public health through the development of policy regarding the rational use of medicines, pharmacy education, pharmacy practice, pharmaceutical industry, and pharmaceutical supply and distribution. In particular, we begin to develop ¡®a community pharmacy model as a health promotion center for community members¡¯. We are collecting and analysing big data accordingly to develop pharmacy-based policies, which pursue maximised pharmacy practice for all the Koreans.

In consequence, KIPPA will consistently implement research tailored to the promotion of health in the nation and worldwide. We kindly ask for supports from our fellow pharmacists, public and associations.

If you have any further enquiries about the institute or research in English, please contact us via e-mail (kippa.org@gmail.com).

Thank you.

Office Address
3FL, 194, Hyoryeong-ro, Seocho-gu, Seoul, Repbulic of Korea

ÇöÀçÀ§Ä¡ : Home : ¾Ë¸²¸¶´ç : °øÁö»çÇ×
   
¾Ë¸²¸¶´ç
°øÁö»çÇ×
º¸µµÀÚ·á
ÀÎÀçä¿ë
 
 
Á¦   ¸ñ [´ëÇѾà»çÀú³Î] ÀǾàǰÁ¤Ã¥¿¬±¸¼Ò ¸®Æ÷Æ®_Á¶±â´ëÀÀü°è¿¡ ÃÖÀûÈ­µÈ ¡®¾à±¹±â¹Ý °¨½Ã ½Ã½ºÅÛ¡¯
³»   ¿ë

ij³ª´Ù ¾à±¹±â¹Ý °¨½Ã ½Ã½ºÅÛ, Pharmacy-based Surveillance System1) 
¾à±¹±â¹Ý °¨½Ã ½Ã½ºÅÛ(Pharmacy-based Surveillance System)2)Àº Ä³³ª´Ù º¸°ÇºÎ »êÇÏ Centre of Food-Borne, Environmental and Zoonotic Infectous Diseases(CFEZID)¿¡¼­ °ü¸®ÇÑ´Ù. 

ÀǾàǰÀÇ ¼Òºñ µ¥ÀÌÅ͸¦ È°¿ëÇÏ¿© Áö¿ªÀα¸ÀÇ Áúº´¾ç»óÀ» °¨½ÃÇϴ ÀÌ ½Ã½ºÅÛÀº ÆÇ¸Å·®ÀÌ Áõ°¡ÇÑ Áö¿ªÀÇ Áúº´È®»ê¿©ºÎ¸¦ ´õ¿í ÁýÁßÀûÀ¸·Î Á¶»çÇÔÀ¸·Î ½á È®»êÁö¿ªÀÇ °èÀý¼º °¨¿°Áúȯ °¨½Ã¿¡ È¿°úÀûÀ¸·Î ÀÛµ¿Çß´Ù. 

?°³¿ä 
ij³ª´Ù º¸°ÇºÎ´Â 2004³â Ã³À½ ¾à±¹±â¹Ý °¨½Ã ½Ã½ºÅÛÀ» °³¹ßÇØ À§Àå °ü°è ÀϹÝÀǾàǰÀ» ¸ð´ÏÅ͸µÇÏ¿© ½Äǰ°ú ¹°À» ¸Å°³·Î ÇÑ Áúº´À» Á¶±â ¹ß°ßÇϱâ À§ÇÑ °¡´É¼ºÀ» Æò°¡ÇϰíÀÚ Çß´Ù. 

2009³â H1N1 À¯Ç༺µ¶°¨ (pH1N1)ÀÇ ¹ßº´¿¡ ´ëóÇϱâ À§ÇØ ½Ã½ºÅÛÀ̠Ȱ¿ëµÆÀ» ´ç½Ã, pH1N1ÀÇ 2Â÷ À¯Çà¿¡ ´ëÇÑ ÈÄÇâÀû ºÐ¼®Àº ¾à±¹±â¹Ý °¨½Ã ½Ã½ºÅÛÀÌ µ¶°¨°ú °°Àº Àü¿°¼º Áúº´À» ¸ð´ÏÅ͸µÇϴµ¥ È¿°úÀûÀΠ¹æ¹ýÀÓÀ» Áõ¸íÇß´Ù. 

pH1N1 ÀÇ À¯Çà ÀÌÈÄ ÁøÅëÁ¦, Ç׾˷¯ÁöÁ¦, Ç׿ì¿ïÁ¦ ±×¸®°í ½ÉÇ÷°ü°è ¾à µî ´Ù¼öÀÇ ÀǾàǰµéÀÇ ÆÇ¸Å·® ¸ð´ÏÅ͸µÀÌ ÀÌ·ïÁ³´Ù(2015³â ÀÌÈÄ Á¾·áµÊ). 

? È¿°ú 
¾à±¹ ÆÇ¸Å µ¥ÀÌÅÍ(ó¹æÀǾàǰ, ÀϹÝÀǾàǰ)´Â ¼Û±Ý ÈÄ ¾à 48½Ã°£ÀÌ ¼Ò¿äµÇ¾î °ÅÀÇ ½Ç½Ã°£ ÀÚ·á¿¡ °¡±õ´Ù. 

À̴ ÀÇ»çÀÇ º¸°í(Influenza-like-illness physician report)º¸´Ù 5¿¡¼­ 8ÀÏÀÌ ºü¸£¸ç, ½ÇÇèÀû È®Áø(laboratory confirmation)º¸´Ù´Â 10-12ÀÏ, È£Èí±â ¹ÙÀÌ·¯½º °Ë»çº¸´Ù´Â 17ÀÏÀÌ Àû°Ô ¼Ò¿äµÈ´Ù. 

¾Æ·¡ ±×·¡ÇÁ¿¡¼­ ¿¹»óµÇ´Â Áúº´ÀÇ ¹ß»ý½ÃÁ¡°ú °¨½Ã¸¦ À§ÇÑ °¢ ÀÚ·á¿øº° µ¥ÀÌÅÍ È®Àο¡ ¼Ò¿äµÇ´Â ±â°£À» ºñ±³ÇØ º¼ ¼ö ÀÖ´Ù. 


¡à Áß±¹ ÅÙÁø(Tianjin)½ÃÀÇ Çõ½ÅÀû µ¶°¨ °¨½Ã ¹æ¾È: OTC Surveillance3) 
Áß±¹Àº °è¼ÓÇØ¼­ À¯Ç༺ µ¶°¨ÀÇ ¹ßº´Áö°¡ µÇ¾î¿ÔÀ¸¸ç, À̴ Áö¿ª°ú ¼¼°èÀÇ °Ç°­¿¡ À§ÇùÀ» °¡Çß´Ù. ÀÌ¿¡ Çõ½ÅÀûÀΠµ¶°¨ °¨½Ãü°èÀÇ ¸¶·ÃÀÌ ½Ã±ÞÇØÁü¿¡ µû¶ó ÅãÁø½Ã¿¡¼­´Â À̸¦ À§ÇØ ³× °¡Áö °¨½Ãü°è¸¦ µµÀÔÇß´Ù: (i)º¸°ÇÀÇ·á½Ã¼³ÀÇ ILI(µ¶°¨À¯»çÁúº´, Influenza-like illness)º¸°í; (ii)ÀϹÝÀǾàǰ ÆÇ¸Å; (iii)Çб³±â¹Ý ILI°¨½Ã; (iv)ÀÎÅͳݠ°Ë»ö Äõ¸®°¨ ½Ã(Baidu Internet search query surveillance)4) 

¡Ü OTC °¨½Ãü°è(OTC Sruveillance) °³¿ä 
°¨½Ã¿¡´Â °¨±â¿Í ±Þ¼ºÈ£Èí±â°¨¿°ÀÇ Ä¡·á¿¡ »ç¿ëµÇ´Â 62°¡ÁöÀÇ ÁöÁ¤ µÈ ÀϹÝÀǾàǰÀÇ ÆÇ¸Åµ¥ÀÌÅ͸¦ »ç¿ëÇß´Ù. Á¤Á¦, ºÐ¸», °ú¸³ ±×¸®°í ½Ã·´ µî ¸ðµç Á¦ÇüÀÇ ÀǾàǰµéÀÌ ¸ÅÀÏ º¸°íµÇ¾úÀ¸¸ç ÅãÁø½Ã º´¿ø ±Ù¹æÀÇ 51°³ ¾à±¹ Áß 18°³ÀÇ ¾à±¹ÀÌ ¹«ÀÛÀ§·Î ¼±ÅõƴÙ. 

°¢ ¾à±¹¿¡¼­ ÆÇ¸Å·® ÀÌ »óÀ§ 5À§ ¾È¿¡ µç Ç°¸ñÀº ÇØ¿­ÁøÅëÁ¦, ÁøÇØÁ¦, °Å´ãÁ¦, ±×¸®°í ´Ù¸¥ ÀüÅë¾àÁ¦ µîÀ̾ú´Ù. 

?°á°ú 
¼±Ç࿬±¸¿¡ µû¸£¸é µ¶°¨¿¡ °É¸° È¯ÀÚµéÀº ÀÇ¿ø ¶Ç´Â ÀÀ±Þ½ÇÀ» ¹æ¹®Çϱ⠺¸´Ù OTC¸¦ ±¸¸ÅÇϴ °æÇâÀÌ ´õ Å©°Ô ³ªÅ¸³­´Ù. 

´ëºÎºÐÀǠȯÀÚµéÀÌ ½É°¢ÇÏÁö ¾ÊÀ» °æ¿ì¿¡´Â OTC¸¦ ÀÌ¿ëÇÑ ÀÚ°¡Ä¡·á¸¦ ¼öÇàÇϴ ¹Ý¸é, Áõ»óÀÌ ½É°¢ÇØÁú ¶§¸¸ ÀÇ·á±â°üÀ» ¹æ¹®Çϱ⠶§¹®ÀÌ´Ù. 

ÀÌ¿¡ ½ÇÁ¦·Î ÅÙÁø½ÃÀÇ OTC °¨½Ã½Ã½ºÅÛÀÌ º´¿ø¿¡¼­ÀÇ È®ÁøÆÇÁ¤º¸´Ù 1ÁÖ ºü¸¥ Áõ°¡Ãß¼¼¸¦ º¸ÀΠ°ÍÀ¸·Î ³ªÅ¸³ª µ¶°¨°ü·Ã OTC ÆÇ¸Å·®ÀÇ Áõ°¡´Â µ¶°¨¹ß»ýÇöȲ ¸ð´ÏÅ͸µ¿¡ À־ٸ¥ ¾î¶² °¨½Ãü°èº¸´Ù ºü¸£°í È¿°úÀûÀΠ°¨½Ã¼ö´ÜÀÌ µÉ ¼ö ÀÖÀ½À» º¸¿©Áá´Ù. 

³ª°¡¸ç 
¿ÃÇØ 1¿ù 20ÀÏ ±¹³»¿¡¼­ ÃÖÃʷΠÄڷγª19 ¹ÙÀÌ·¯½º °¨¿°Áõ È¯ÀÚ°¡ È®ÀεǸ鼭 ½ÃÀ۵Ƞ½ÅÁ¾Äڷγª¹ÙÀÌ·¯½º»çÅ´ ±¹¹ÎÀÇ °Ç°­À» Å°±â±â À§Çؼ­´Â ½Å¼ÓÇÑ °ü·Ã Á¤º¸ ¼öÁý°ú ´õºÒ¾î ÀûÀýÇÑ °¨¿°º´ ´ëÀÀ ½Ã½ºÅÛ °¡µ¿ÀÌ ÇʼöÀûÀÓÀ» ´À³¢°Ô Çϴ °è±â¸¦ Á¦°øÇÏ¿´´Ù.

»ç½Ç À̹ø »çÅ´ ½ÅÁ¾Äڷγª¹ÙÀÌ·¯½ºÀÇ Áø¿øÁöÀΠÁß±¹¿¡¼­ ¹ßº´ Ãʱ⿡ Á» ´õ ½Å¼ÓÇÏ°íµµ Àû±ØÀûÀΠÁ¶±â ´ëÀÀ Ã¼°è¸¦ ¸¶·ÃÇϰí Àû¿ëÇÏ¿´´Ù¸é °¨¿°º´ È®»ê ¹üÀ§¸¦ ÃÖ¼ÒÈ­ ½Ãų ¼öµµ ÀÖ¾ú´Ù´Â ¾Æ½¬¿òÀÌ ³²´Â´Ù. 

±×·±µ¥, Áß±¹¿¡¼­´Â ¿ìÇÑ¿¡¼­ ÃÖÃÊ ÀǽÉȯÀÚ°¡ ¹ß»ýÇÏ¿´À» ¶§ Á¦´ë·Î µÈ °Ý¸® Á¶Ä¡°¡ ÀÌ·ç¾îÁöÁö ¾Ê¾Ò±â ¶§¹®¿¡ Áö¿ª»çȸ °¨¿°Àº ¹°·Ð Áß±¹ Àü¿ª°ú Å¸ ±¹°¡·Î±îÁöÀÇ È®»êÀ» ¸·Áö ¸ø ÇÑ °ÍÀÌ´Ù. 

À̿͠°°Àº ½Ç¼ö¸¦ ´Ù½Ã´Â ÇÏÁö ¾Ê±â À§Çؼ­´Â Áß±¹»Ó¸¸ ¾Æ´Ï¶ó ¿ì¸®³ª¶ó¿¡¼­µµ º¸°ÇÀÇ·á½Ã½ºÅÛÀÇ ÃÖÀü¹æ¿¡ ÀÖÀ¸¸é¼­ ÀǽÉȯÀÚ ¶Ç´Â À¯Áõ»óÀÚ°¡ °¡Àå ¸ÕÀú Á¢±ÙÇÒ ¼ö Àִ ½Ã¼³ÀΠÁö¿ª¾à±¹ÀÇ ¿ªÇÒÀÌ ¸Å¿ì Áß¿äÇÏ´Ù°í ÇϰڴÙ. 

ÀÌ¿¡ Áö¿ª¾à±¹¿¡ ÀǽɵǴ ȯÀÚ°¡ ¹æ¹®ÇßÀ» °æ¿ì FIP ÁöħÀ» Àû¿ëÇÏ¿© ´ë»ó È¯ÀÚ¸¦ °Ý¸® Á¶Ä¡Çϰí, º¸°Ç´ç±¹À» ÅëÇØ ÀûÁ¤ º¸°Ç ÀÇ·á½Ã¼³·Î À̼ÛÇϴ µîÀÇ ±âº»ÀûÀΠ´ëÀÀü°è°¡ »ó½Ã °¡µ¿µÇ¾î¾ß ÇÒ °ÍÀÌ´Ù. 

»Ó¸¸ ¾Æ´Ï¶ó ÃÖ±Ù ¹æ¿ª´ç±¹ÀÌ Äڷγª 19¸¦ °èÀý¼º µ¶°¨Ã³·³ »ó½Ã °¨½Ã´ë»óÀ¸·Î Æ÷ÇÔÇÑ´Ù°í ¹àÈù ¹Ù¿Í °°ÀÌ, À̹ø ±âȸ¿¡ ±¸±ÛÀÇ ¡®ÇÃ·ç Æ®·»µå¡¯³ª Ä³³ª´ÙÀÇ ¾à±¹±â¹Ý °¨½Ã½Ã½ºÅÛÀ̳ª Áß±¹ÀÇ OTC °¨½Ãü°è¿Í °°Àº ¾à±¹ °ü·Ã ºòµ¥ÀÌÅ͸¦ È°¿ëÇÑ Áúº´¸ð´ÏÅ͸µÃ¼°è°¡ »õ·Ó°Ô µµÀÔµÇ°í °­È­µÇ´Â µîÀÇ ¹üÁ¤ºÎÂ÷¿øÀÇ Áö¿ª»çȸ»Ó¸¸ ¾Æ´Ï¶ó ±¹°¡ °£ °¨¿° ¿¹¹æ(¹æÁö)¸¦ À§ÇÑ ½Å¼ÓÇÑ ´ëÀÀÃ¥ ¸¶·ÃÀÌ ¿ä±¸µÈ´Ù. 

<ºÎ·Ï : FIP Á¦°ø ½ÅÁ¾ Äڷγª¿Í °ü·ÃµÈ À߸øµÈ Á¤º¸ ¶Ç´Â ¹ÏÀ½>
1. ½ÅÁ¾Äڷγª´Â ³ëÀΠȤÀº Áöº´ÀÌ Àִ »ç¶÷µé¸¸ °¨¿°À§Ç輺ÀÌ ÀÖ´Ù?!
: ¾Æ´Ï´Ù. ¸ðµç ¿¬·ÉÃþÀÌ Äڷγª¹ÙÀÌ·¯½º¿¡ °¨¿°µÉ ¼ö ÀÖ´Ù. ¿¬·ÉÀÌ ³ôÀº ºÐµéÀ̳ª Ãµ½Ä, ´ç´¢, ½ÉÀåÁúȯ µîÀÇ Áöº´ÀÌ Àִ ºÐµéÀÇ °æ¿ì ¹ÙÀÌ·¯½º¿¡ ÀÇÇÑ À¯µ¶ ±Ø½ÉÇÑ Áõ¼¼°¡ ³ªÅ¸³ª±â ½¬¿î °ÍÀÌ´Ù. ¼¼°èº¸°Ç±â±¸´Â ¸ðµç ¿¬·ÉÃþÀÇ »ç¶÷µéÀÌ ¼Õ ¾Ä±â À§»ý¼öÄ¢°ú È£Èí±â À§»ý¼öÄ¢¿¡ µû¸§À¸·Î½á Äڷγª¹ÙÀÌ·¯½º·ÎºÎÅÍ ÀڽŵéÀ» º¸È£Çϵµ·Ï ±Ç°íÇϰí ÀÖ´Ù(¼¼°èº¸°Ç±â±¸, 2020).

2. ¸¶´Ã ¼·Ãë°¡ Äڷγª¹ÙÀÌ·¯½º °¨¿° ¿¹¹æ¿¡ µµ¿òÀÌ µÈ´Ù?!
: ¸¶´ÃÀº ¹Ì»ý¹°ÀÇ ¼ºÀå°ú ¹ø½ÄÀ» ´õµð°Ô ÇØÁִ Ç׹̻ý¹° ¼ºÁúÀ» °¡Áø °Ç°­¿¡ ÁÁÀº À½½ÄÀÌ´Ù. ÇÏÁö¸¸ ÇØ´ç ¹ÙÀÌ·¯½º¿¡ ´ëÇØ ¸¶´ÃÀÌ ¿¹¹æ È¿°ú¸¦ °¡Áø´Ù´Â Áõ°Å´Â ¾îµð¿¡µµ ¾ø´Ù.

3. Âü±â¸§À» ¹Ù¸£´Â °ÍÀº Äڷγª¹ÙÀÌ·¯½º°¡ ¸ö¿¡ Ä§ÅõÇϴ °ÍÀ» ¸·¾ÆÁØ´Ù?!
: ¾Æ´Ï´Ù. Âü±â¸§Àº Äڷγª¹ÙÀÌ·¯½º¸¦ Á×ÀÌÁö ¾Ê´Â´Ù. Ç¥¸é¿¡ Àû¿ëÇÏ¿© Äڷγª¹ÙÀÌ·¯½º¸¦ Á×ÀÏ ¼ö Àִ ȭÇÐÀû ¼Òµ¶¾àµé·Î Ç¥¹é/¿°¼Ò°è ¼Òµ¶¾à, ¿¡Å׸£ ¿ë¸Å, 75% ¿¡Åº¿Ã, °ú»êÈ­¾Æ¼¼Æ®»ê ±× ¸®°í Å¬·Î·ÎÆ÷¸§ÀÌ ÀÖ´Ù. ÇÏÁö¸¸ Á¦½ÃµÈ ¼Òµ¶¾àµéÀ» ÇǺο¡ ¹Ù¸£°Å³ª ÄÚ ¹Ø¿¡ ¹Ù¸£´Â °ÍÀº ¹ÙÀÌ·¯½º¿¡ È¿°ú°¡ ¹Ì¾àÇϸç, ¿ÀÈ÷·Á ÀÎü¿¡ À¯µ¶ÇÏ´Ù.


ÂüÁ¶¹®Çå
1) Muchaal et al, Canada Communicable Disease Report, Public Health Agency of Canada, 2015, pp.203-208. 
2) Government of Canada, ¡°Pharmacy Surveillance-Analytical Services (1000156022)¡±, https:// buyandsell.gc.ca/procurement-data/tender-notice/PW-14-00623858, (Feb, 03, 2020). 
3) Dong et al, ¡°Syndromic surveillance for in-uenza in Tianjin, China: 2013-14¡±, Journal of Public Health, 39(2), 2016, pp.274-281. 
4) ¸ð´ÏÅ͸µÀº 2013-14³âµµÀÇ µ¶°¨À¯Ç࠽ñâÀΠ2013³â 9¿ù 30ÀϺÎÅÍ 2014³â 3¿ù 30ÀϱîÁö ½ÃÇàµÇ¾ú´Ù.


[±â»çÃâó] https://www.kpanews.co.kr/academy/show.asp?page=1&search_cate=8&idx=69


 

¹øÈ£ ÷ºÎ Á¦¸ñ ÀÛ¼ºÀÚ ÀÛ¼ºÀÏ Á¶È¸
168 û³â¾à»ç¿Í ¾à´ë»ýÀ» À§ÇÑ Ä¿¸®¾î °³¹ß °¡À̵åºÏ ÃÖÀ±Á¤ 2022-02-14 2540
167 2020³â ±âºÎ±Ý ¸ðÁý ¹× ÁöÃâ ¸í¼¼¼­ ÀÌÁö¿¬ 2021-05-10 1486
166 [ȯÀÚ¾ÈÀü º¸°íÇнÀ ½Ã½ºÅÛ] '¾à±¹ ¾àÁ¦¾÷¹« °ü¸®Áöħ ¾È³»' °Ô½Ã ±èÁøÀÌ 2020-06-25 3602
165 2021 ÀǾàǰÁ¤Ã¥¿¬±¸¼Ò ¿¬±¸¿ø ä¿ë °ø°í °ü¸®ÀÚ 2020-03-12 6739
164 [´ëÇѾà»çÀú³Î] ÀǾàǰÁ¤Ã¥¿¬±¸¼Ò ¸®Æ÷Æ®_Á¶±â´ëÀÀü°è¿¡ ÃÖÀûÈ­µÈ ¡®¾à±¹±â¹Ý °¨½Ã ½Ã½ºÅÛ¡¯ ±è¼±Èñ 2020-02-26 3592
163 [´ëÇѾà»çÀú³Î] ÀǾàǰÁ¤Ã¥¿¬±¸¼Ò ¸®Æ÷Æ®_Äڷγª19 ´ëÀÀ FIP ½Å±Ô °¡À̵å¶óÀÎ ±è¼±Èñ 2020-02-26 3172
162 [´ëÇѾà»çÀú³Î] ÀǾàǰÁ¤Ã¥¿¬±¸¼Ò ¸®Æ÷Æ®_¼¼°è ¾à±¹µéÀÇ °¨¿°¼º Áúȯ °¨½Ã ¹× ´ëÀÀ »ç·Ê ¼Ò°³ 1Æí ±è¼±Èñ 2020-02-12 2068
161 "¾à·á»ç¾÷ ³Ñ¾î Áö¿ª Á᫐ ¾à±¹ °Ç°­Çãºê ¿ªÇÒ Èû¾µ °Í" ±è¼±Èñ 2020-01-30 1668
160 "¾à±¹ '°Ç°­ÁõÁø Çãºê' ¹æÇâÀ¸·Î °¡¾ß"...·¹Áö½ºÆ®¸® ±¸Ãà º»°ÝÈ­ ±è¼±Èñ 2020-01-30 1478
159 [´ëÇѾà»çÀú³Î/ÀǾàǰÁ¤Ã¥¿¬±¸¼Ò ¸®Æ÷Æ®]¿µ±¹ ¾à±¹, °Ç°­ »ýȰ ¼¾ÅÍ·Î ¹ßµ¸¿ò ±è¼±Èñ 2020-01-30 1668
158 [´ëÇѾà»çÀú³Î/ÀǾàǰÁ¤Ã¥¿¬±¸¼Ò ¸®Æ÷Æ®]È£ÁÖ, ¹æ¹® ¾à·á µµÀÔÇØ ¾à¹° ¿ä¹ý ÇýÅà ±Ø´ëÈ­ ±è¼±Èñ 2020-01-30 1380
157 [´ëÇѾà»çÀú³Î/ÀǾàǰÁ¤Ã¥¿¬±¸¼Ò ¸®Æ÷Æ®]ÀϺ», ¡®´Ü°ñ¾à»ç-ÀçÅù湮¿Ï·á¡¯ È£Æò ¼Ó Ȱ¼ºÈ­ ±è¼±Èñ 2020-01-30 1472
156 [´ëÇѾà»çÀú³Î/ÀǾàǰÁ¤Ã¥¿¬±¸¼Ò ¸®Æ÷Æ®]±¹³»¿Ü »ç·Ê°íÂûÀ» ÅëÇÑ Ä¿¹Â´ÏƼ Äɾ¼­ÀÇ Áö¿ª¾à±¹ ¹× ¾à»ç ¿ªÇÒ Å½»ö 1 ±è¼±Èñ 2020-01-30 1372
155 [±â»ç]ÀǾàǰÁ¤Ã¥¿¬±¸¼Ò, ÆÐ³Î¾à±¹ ¸ðÁý Ȱµ¿ Àü°³ ±è¼±Èñ 2019-11-13 1537
154 [±â»ç]¾à±¹¸¸ÀÇ Ã¼°èÀû Á¤Ã¥¼ö¸³À§ÇÑ ¾à±¹DB ±¸Ãà 'ù¹ß' ±è¼±Èñ 2019-11-13 1443

ÀÌÀü 10ÆäÀÌÁö [1]  [2]  [3]  [4]  [5]  [6]  [7]  [8]  [9]  [10]  ´ÙÀ½ 10ÆäÀÌÁö

 
 

¼­¿ï ¼­Ãʱ¸ È¿·É·Î194, 3Ãþ (Àç)ÀǾàǰÁ¤Ã¥¿¬±¸¼Ò TEL : 02) 3474-5301 / FAX : 02)3474-5306

COPYRIGHT (C) 2006 KOREA INSTITUTE FOR PHARMACEUTICAL POLICY AFFAIRS ALL RIGHTS RESERVED. FOR MORE INFORMATION MAL kippa.org@gmail.com

±âºÎ±Ý ¾È³»